Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.36 |
| ▸ | BRD4 | O60885 | 5/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.31 |
| ▸ | ERN1 | O75460 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2146856 | 1.00 | ESR1 (0.36) | ESR1ESR2BRD4SMN1; SMN2LMNA | |
| SCHEMBL2146284 | 0.88 | ERN1 (0.36) | ESR1ESR2BRD4LMNAERN1 | |
| SCHEMBL2146286 | 0.88 | ERN1 (0.36) | ESR1ESR2BRD4LMNAERN1 | |
| SCHEMBL2146933 | 0.84 | ESR2 (0.39) | ESR1ESR2BRD4LMNAALOX15 | |
| SCHEMBL2146930 | 0.84 | ESR2 (0.39) | ESR1ESR2BRD4LMNAALOX15 | |
| SCHEMBL2146755 | 0.80 | BRD4 (0.36) | BRD4SMN1; SMN2LMNAERN1 | |
| SCHEMBL2146748 | 0.80 | BRD4 (0.36) | BRD4SMN1; SMN2LMNAERN1 | |
| SCHEMBL2312706 | 0.80 | PIK3CD (0.38) | ESR1ESR2BRD4LMNAABCB1 | |
| SCHEMBL2146718 | 0.80 | ERN1 (0.35) | ESR1ESR2BRD4LMNAERN1 | |
| SCHEMBL2146723 | 0.80 | ERN1 (0.35) | ESR1ESR2BRD4LMNAERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102216268-A | Novel estrogen receptor ligands | KAROBIO AB | 2011-10-12 | — | — | CN | claimed |
| US-20110201555-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2011-08-18 | — | — | US | claimed |
| EP-2346824-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2011-07-27 | — | — | EP | claimed |
| WO-2010031852-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2010-03-25 | — | — | WO | claimed |
| US-20110201555-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2011-08-18 | — | — | US | disclosed |
| EP-2346824-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010031852-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201555-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | ESR1, ESRRA, GPER1 | ESR1 1/4885ESR2 4/4885BRD4 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.